CNCE Key Statistics, Chart & Performance
The current stock price of CNCE is 8.37 USD. In the past month the price decreased by -0.36%. In the past year, price increased by 190.63%.
CNCE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.77B | ||
| AMGN | AMGEN INC | 15.1 | 177.79B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.98 | 118.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 796.86 | 53.69B | ||
| INSM | INSMED INC | N/A | 37.34B | ||
| NTRA | NATERA INC | N/A | 34.33B | ||
| BIIB | BIOGEN INC | 10.91 | 26.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.05 | 21.65B | ||
| INCY | INCYTE CORP | 16.61 | 20.94B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About CNCE
Company Profile
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. The company is headquartered in Lexington, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2014-02-13. The firm is focused on developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 (JAK 1/2) inhibitor that discovered through deuterated chemical entity Platform (DCE platform). The firm is evaluating CTP-543 in a Phase III clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. Through DCE Platform, the Company has discovered and developed novel drugs designed to have properties, including enhanced clinical safety, tolerability or efficacy based on compounds. DCE technology has range of potential across numerous therapeutic areas, including for chronic diseases for which medicines are continually used by patients. The firm is assessing earlier-stage pipeline candidates as potential development candidates, including a once-daily, modified release formulation of CTP-543.
Company Info
CONCERT PHARMACEUTICALS INC
Suite 500, 99 Hayden Avenue
Lexington MASSACHUSETTS 02421 US
CEO: Roger D. Tung
Employees: 64
Phone: 17818600045.0
CONCERT PHARMACEUTICALS INC / CNCE FAQ
What does CNCE do?
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. The company is headquartered in Lexington, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2014-02-13. The firm is focused on developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 (JAK 1/2) inhibitor that discovered through deuterated chemical entity Platform (DCE platform). The firm is evaluating CTP-543 in a Phase III clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. Through DCE Platform, the Company has discovered and developed novel drugs designed to have properties, including enhanced clinical safety, tolerability or efficacy based on compounds. DCE technology has range of potential across numerous therapeutic areas, including for chronic diseases for which medicines are continually used by patients. The firm is assessing earlier-stage pipeline candidates as potential development candidates, including a once-daily, modified release formulation of CTP-543.
Can you provide the latest stock price for CONCERT PHARMACEUTICALS INC?
The current stock price of CNCE is 8.37 USD. The price increased by 0.12% in the last trading session.
What is the dividend status of CONCERT PHARMACEUTICALS INC?
CNCE does not pay a dividend.
What is the ChartMill rating of CONCERT PHARMACEUTICALS INC stock?
CNCE has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is CONCERT PHARMACEUTICALS INC (CNCE) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CNCE.
What is CONCERT PHARMACEUTICALS INC worth?
CONCERT PHARMACEUTICALS INC (CNCE) has a market capitalization of 401.95M USD. This makes CNCE a Small Cap stock.
Can you provide the upcoming earnings date for CONCERT PHARMACEUTICALS INC?
CONCERT PHARMACEUTICALS INC (CNCE) will report earnings on 2023-05-03.
CNCE Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to CNCE. When comparing the yearly performance of all stocks, CNCE is one of the better performing stocks in the market, outperforming 99.23% of all stocks.
CNCE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CNCE. The financial health of CNCE is average, but there are quite some concerns on its profitability.
CNCE Financial Highlights
Over the last trailing twelve months CNCE reported a non-GAAP Earnings per Share(EPS) of -3.21. The EPS decreased by -62.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CNCE Forecast & Estimates
11 analysts have analysed CNCE and the average price target is 11.9 USD. This implies a price increase of 42.17% is expected in the next year compared to the current price of 8.37.
For the next year, analysts expect an EPS growth of -22.75% and a revenue growth -99.69% for CNCE